Inhaled pentamidine plus oral miltefosine for mucosal leishmaniasis
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests a combination of two medicines—inhaled pentamidine and oral miltefosine—to treat mucosal leishmaniasis, a parasitic infection of the nose, mouth, and throat. It may be an option for people in Bolivia who have not been treated recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You weigh more than 45 kg (about 99 pounds).
- You have leishmaniasis that affects your nose, mouth, throat, or voice box, confirmed by a lab test or a skin test plus a scar and living in an area where the disease exists.
- You have not had any leishmaniasis treatment in the last 12 months (unless that treatment ended more than 12 months ago and your disease has not improved in the last 6 months).
- You do not have other serious health problems that could interfere with the treatment.
- If you are a woman of childbearing age, you must use two forms of birth control for 5 months after starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well miltefosine works for people with leishmaniasis, a skin infection from a parasite. It aims to find the best way to use this medicine to help patients get better.
This study tests two new oral medicines (called LXE408) against an existing oral treatment (miltefosine) for people with a first episode of localized cutaneous leishmaniasis (skin sores caused by a parasite). The goal is to see if the new medicines are safe and work better at healing the sores.
This study compares different drugs to find the best one for treating cutaneous leishmaniasis, a skin infection that causes sores. You might get one of several treatments, and the goal is to see which works best and is safest for patients like you.
This study tests a gel containing miltefosine (a medicine) applied directly to the skin sores caused by cutaneous leishmaniasis. The goal is to see if the gel is safe and works to clear the sores.
This trial tests whether adding a special laser treatment (fractional CO₂ laser) to the standard injected medicine (Glucantime) helps heal skin sores from a parasite infection better than the medicine alone. It may offer a more effective way to clear the sores and improve healing.
This study tests whether adding a special medicine (an antimicrobial adjuvant) to the standard treatment for complicated skin sores caused by leishmaniasis can improve healing. It is for people in Ethiopia with sores that are large, many, or in sensitive areas.
Hear when a new Mucosal Leishmaniasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.